sorafenib has been researched along with Leukemia, Myelomonocytic, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L | 1 |
| Duyster, J; Menzel, H; Peschel, C; Rummelt, C; Sigl, M; von Bubnoff, N | 1 |
| Bardet, V; Boudou Rouquette, P; Bouscary, D; Chapuis, N; Chesnais, V; Coriat, R; Fontenay, M; Kaltenbach, S; Kosmider, O; Mayeux, P; Radford-Weiss, I; Tamburini, J; Willems, L | 1 |
3 other study(ies) available for sorafenib and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myelomonocytic, Chronic; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Hematopoiesis; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Niacinamide; Nucleic Acid Hybridization; Phenylurea Compounds; Sorafenib | 2013 |